Roche Holding AG Virtual Event on Key Ophthalmology Data Presented at the Angiogenesis 2022 Meeting Transcript
Ladies and gentlemen, welcome to Roche Angiogenesis 2022 Meeting. My name is Marco, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. (Operator Instructions)
At this time, it is my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Thanks, Marco. Can I have the first slide, please? Next one, please. So welcome to our event, and let me quickly guide you through today's agenda. We have 3 speakers with us. So first of all, Nilesh Mehta, our global franchise head in ophthalmology. He will present an update on our overall franchise strategy. And then we have Christopher Brittain with us, our Vice President and Global Head of Ophthalmology Product Development, who will provide you an update on our growing clinical development pipeline. And finally, last but not least, we have Nancy Holekamp with us, a well-known retina specialist and also a Vabysmo clinical investigator, who will lead us through the 2-year data of Vabysmo and Susvimo, which we have just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |